Gracell Biotechnologies (shanghai) Co., Ltd.
Clinical trials sponsored by Gracell Biotechnologies (shanghai) Co., Ltd., explained in plain language.
Clinical-stage biopharmaceutical company developing cell therapies for cancer.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Experimental CAR t therapy takes aim at stubborn AL amyloidosis
Disease control Recruiting nowThis early-phase trial is testing a new treatment called GC012F for people with AL amyloidosis that has come back or not responded to other therapies. GC012F is a type of immunotherapy that uses a patient's own immune cells, modified to attack two specific targets on the abnormal…
Phase: PHASE1 • Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Double-Pronged attack: new CAR T-Cell therapy targets Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests a new treatment called GC012F for people with multiple myeloma that has come back or not responded to at least three prior treatments. GC012F is a type of immunotherapy that uses a patient's own immune cells, modified to recognize and attack myeloma cells using t…
Phase: PHASE1, PHASE2 • Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC